Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Effects of phosphodiesterase 3/4 inhibition on matrixmetalloproteinases 2 and 9 in chronic experimental pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 435s Year: 2004
Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003
Increased rho-kinase activity is related to pulmonary endothelial dysfunction in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008
Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Increased expression of phosphodiesterase 4 (PDE4) A, B and D in alveolar macrophages from chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2011 - Macrophages and neutrophils in chronic lung disease Year: 2011
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 488-496 Year: 2002
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Role of Rho-kinase pathway in et-1-induced vasoconstriction in pulmonary artery of chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009
Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006
Physiological effects of roflumilast at rest and during exercise in COPD Source: Eur Respir J 2012; 39: 1104-1112 Year: 2012
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
Tissue inhibitor of metalloproteinases-;2 gene polymorphisms in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 748-752 Year: 2001
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Source: Eur Respir Rev 2007; 16: 105-112 Year: 2007